The clarification has been induced by the Serum Institute of India (SSI), the institute which can be seen entering a manufacturing partnership with AstraZeneca to produce Oxford University’s Covid-19 vaccine this is a denial for the reports that the shot may be launched in 73 days as ‘completely false and conjectural’. This report has been wholly denied.
In the clarification that is given by the serum institute says that the government has granted it permission to only manufacture Covishield and stockpile . It has also said that Covishield will be commercialised once trials are proven successful and regulatory approvals are in place.
Serum Institute has registered for Phase II and III clinical trials on Covishield with the Clinical Trials Registry of India (CTRI). The trials will be conducted on 1,600 healthy participants across India.